Patients with AR-positive TNBC usually have lower tumor recurrence rates and longer survival times. They are less sensitive to chemotherapy and more sensitive to AR inhibitors, PI3K inhibitors and their combinations. This evidence concerns the gene PIK3CA and neoplasm.